Novo Nordisk STEP Young trial positive results
Analysis based on 9 articles · First reported Sep 07, 2026 · Last updated Sep 07, 2026
The positive results could expand semaglutide's label to younger children, potentially increasing sales and strengthening Novo Nordisk's position in the obesity market. The news may boost investor sentiment and support the stock price.
Novo Nordisk announced positive results from the STEP Young phase 3 trial evaluating once-weekly semaglutide in children aged 6 to under 12 with obesity. The trial met its primary endpoint, showing superior BMI reduction at week 68 compared with placebo. 40.4% of children treated with semaglutide were no longer classified as having obesity, versus none in the placebo group. Safety and tolerability were consistent with previous trials. The results will be presented at ObesityWeek 2026 in November.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard